Adam M Brickman1, Giuseppe Tosto1, Jose Gutierrez1, Howard Andrews1, Yian Gu1, Atul Narkhede1, Batool Rizvi1, Vanessa Guzman1, Jennifer J Manly1, Jean Paul Vonsattel1, Nicole Schupf1, Richard Mayeux2. 1. From the Taub Institute for Research on Alzheimer's Disease and the Aging Brain (A.M.B., G.T., H.A., Y.G., A.N., B.R., V.G., J.J.M., J.P.V., N.S., R.M.), The Gertrude H. Sergievsky Center (A.M.B., G.T., H.A., Y.G., J.J.M., N.S., R.M.), and the Departments of Neurology (A.M.B., G.T., J.G., Y.G., J.J.M., N.S., R.M.), Pathology and Cell Biology (J.P.V.), and Psychiatry (R.M.), College of Physicians and Surgeons, and Departments of Biostatistics (H.A.) and Epidemiology (N.S., R.M.), Mailman School of Public Health, Columbia University, New York, NY. 2. From the Taub Institute for Research on Alzheimer's Disease and the Aging Brain (A.M.B., G.T., H.A., Y.G., A.N., B.R., V.G., J.J.M., J.P.V., N.S., R.M.), The Gertrude H. Sergievsky Center (A.M.B., G.T., H.A., Y.G., J.J.M., N.S., R.M.), and the Departments of Neurology (A.M.B., G.T., J.G., Y.G., J.J.M., N.S., R.M.), Pathology and Cell Biology (J.P.V.), and Psychiatry (R.M.), College of Physicians and Surgeons, and Departments of Biostatistics (H.A.) and Epidemiology (N.S., R.M.), Mailman School of Public Health, Columbia University, New York, NY. rpm2@columbia.edu.
Abstract
OBJECTIVE: To develop, replicate, and validate an MRI-based quantitative measure of both cerebrovascular and neurodegeneration in Alzheimer disease (AD) for clinical and potentially research purposes. METHODS: We used data from a cross-sectional and longitudinal community-based study of Medicare-eligible residents in northern Manhattan followed every 18-24 months (n = 1,175, mean age 78 years). White matter hyperintensities, infarcts, hippocampal volumes, and cortical thicknesses were quantified from MRI and combined to generate an MRI measure associated with episodic memory. The combined MRI measure was replicated and validated using autopsy data, clinical diagnoses, and CSF biomarkers and amyloid PET from the Alzheimer's Disease Neuroimaging Initiative. RESULTS: The quantitative MRI measure was developed in a group of community participants (n = 690) and replicated in a similar second group (n = 485). Compared with healthy controls, the quantitative MRI measure was lower in patients with mild cognitive impairment and lower still in those with clinically diagnosed AD. The quantitative MRI measure correlated with neurofibrillary tangles, neuronal loss, atrophy, and infarcts at postmortem in an autopsy subset and was also associated with PET amyloid imaging and CSF levels of total tau, phosphorylated tau, and β-amyloid 42. The MRI measure predicted conversion to MCI and clinical AD among healthy controls. CONCLUSION: We developed, replicated, and validated an MRI measure of cerebrovascular and neurodegenerative pathologies that are associated with clinical and neuropathologic diagnosis of AD and related to established biomarkers.
OBJECTIVE: To develop, replicate, and validate an MRI-based quantitative measure of both cerebrovascular and neurodegeneration in Alzheimer disease (AD) for clinical and potentially research purposes. METHODS: We used data from a cross-sectional and longitudinal community-based study of Medicare-eligible residents in northern Manhattan followed every 18-24 months (n = 1,175, mean age 78 years). White matter hyperintensities, infarcts, hippocampal volumes, and cortical thicknesses were quantified from MRI and combined to generate an MRI measure associated with episodic memory. The combined MRI measure was replicated and validated using autopsy data, clinical diagnoses, and CSF biomarkers and amyloid PET from the Alzheimer's Disease Neuroimaging Initiative. RESULTS: The quantitative MRI measure was developed in a group of community participants (n = 690) and replicated in a similar second group (n = 485). Compared with healthy controls, the quantitative MRI measure was lower in patients with mild cognitive impairment and lower still in those with clinically diagnosed AD. The quantitative MRI measure correlated with neurofibrillary tangles, neuronal loss, atrophy, and infarcts at postmortem in an autopsy subset and was also associated with PET amyloid imaging and CSF levels of total tau, phosphorylated tau, and β-amyloid 42. The MRI measure predicted conversion to MCI and clinical AD among healthy controls. CONCLUSION: We developed, replicated, and validated an MRI measure of cerebrovascular and neurodegenerative pathologies that are associated with clinical and neuropathologic diagnosis of AD and related to established biomarkers.
Authors: William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Seonjoo Lee; Fawad Viqar; Molly E Zimmerman; Atul Narkhede; Giuseppe Tosto; Tammie L S Benzinger; Daniel S Marcus; Anne M Fagan; Alison Goate; Nick C Fox; Nigel J Cairns; David M Holtzman; Virginia Buckles; Bernardino Ghetti; Eric McDade; Ralph N Martins; Andrew J Saykin; Colin L Masters; John M Ringman; Natalie S Ryan; Stefan Förster; Christoph Laske; Peter R Schofield; Reisa A Sperling; Stephen Salloway; Stephen Correia; Clifford Jack; Michael Weiner; Randall J Bateman; John C Morris; Richard Mayeux; Adam M Brickman Journal: Ann Neurol Date: 2016-04-27 Impact factor: 10.422
Authors: Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327
Authors: Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk Journal: Arch Neurol Date: 2008-11
Authors: Kirsty E McAleese; Lauren Walker; Sophie Graham; Elisa L J Moya; Mary Johnson; Daniel Erskine; Sean J Colloby; Madhurima Dey; Carmen Martin-Ruiz; John-Paul Taylor; Alan J Thomas; Ian G McKeith; Charles De Carli; Johannes Attems Journal: Acta Neuropathol Date: 2017-06-21 Impact factor: 17.088
Authors: Val J Lowe; Emily S Lundt; Sabrina M Albertson; Scott A Przybelski; Matthew L Senjem; Joseph E Parisi; Kejal Kantarci; Bradley Boeve; David T Jones; David Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray Journal: Alzheimers Dement Date: 2019-06-04 Impact factor: 21.566
Authors: Angel Piriz; Dolly Reyes; Atul Narkhede; Vanessa A Guzman; Fawad Viqar; Irene B Meier; Mariana Budge; Pedro Mena; Stephen Dashnaw; Joseph Lee; Christiane Reitz; Jose Gutierrez; Luis Campos; Martin Medrano; Rafael Lantigua; Richard Mayeux; Adam M Brickman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Kay C Igwe; Patrick J Lao; Robert S Vorburger; Arit Banerjee; Andres Rivera; Anthony Chesebro; Krystal Laing; Jennifer J Manly; Adam M Brickman Journal: Magn Reson Imaging Date: 2021-10-16 Impact factor: 2.546
Authors: Jose Gutierrez; Tiffany N Porras; Moka Yoo-Jeong; Farid Khasiyev; Kay C Igwe; Krystal K Laing; Adam M Brickman; Marykay Pavol; Rebecca Schnall Journal: J Acquir Immune Defic Syndr Date: 2021-09-01 Impact factor: 3.771
Authors: Bessie C Stamm; Patrick J Lao; Batool Rizvi; Juliet Colon; Kay Igwe; Anthony G Chesebro; Benjamin Maas; Nicole Schupf; Richard Mayeux; Jennifer J Manly; Adam M Brickman Journal: J Gerontol A Biol Sci Med Sci Date: 2020-10-15 Impact factor: 6.053
Authors: Aaron Y Lai; Illsung L Joo; Arunachala U Trivedi; Adrienne Dorr; Mary E Hill; Bojana Stefanovic; JoAnne McLaurin Journal: Brain Res Date: 2021-02-12 Impact factor: 3.252
Authors: Melissa Lamar; Sue Leurgans; Alifiya Kapasi; Lisa L Barnes; Patricia A Boyle; David A Bennett; Konstantinos Arfanakis; Julie A Schneider Journal: Stroke Date: 2021-10-04 Impact factor: 7.914
Authors: Bret R Rutherford; C Jean Choi; Jongwoo Choi; Ben Mass; Xiaofu He; Kaleigh O'Boyle; Joel Sneed; Patrick J Brown; Adam Brickman; Melanie M Wall; Steven P Roose Journal: Am J Geriatr Psychiatry Date: 2020-11-06 Impact factor: 7.996
Authors: Melissa Lamar; Elizabeth A Boots; Konstantinos Arfanakis; Lisa L Barnes; Julie A Schneider Journal: Neuropsychol Rev Date: 2020-10-03 Impact factor: 7.444
Authors: Ramon Casanova; Fang-Chi Hsu; Ryan T Barnard; Andrea M Anderson; Rajesh Talluri; Christopher T Whitlow; Timothy M Hughes; Michael Griswold; Kathleen M Hayden; Rebecca F Gottesman; Lynne E Wagenknecht Journal: Alzheimers Dement Date: 2021-07-26 Impact factor: 16.655